Selling shares during a market downturn locks in losses permanently, but two overlooked dividend stocks offer a way to fund retirement expenses without ever touching your principal.

Alkermes NASDAQ: ALKS reported third-quarter 2026 results marked by 31% year-over-year growth in proprietary product sales, while management highlighted continued investment in its orexin development portfolio across sleep, neuropsychiatric and neurological disorders.

Amneal Pharmaceuticals NASDAQ: AMRX reported third-quarter 2026 revenue of $863 million, up 10% from a year earlier, as growth in affordable medicines and specialty products more than offset an expected decline at its AvKARE business. Adjusted EBITDA rose 30% to $207 million, while adjusted earnings per share increased 53% to $0.26.

BioNTech NASDAQ: BNTX reported third-quarter 2026 revenue of €1.3 billion, down from €1.5 billion a year earlier, as lower demand for its COVID-19 vaccine weighed on results. The company raised the midpoint of its full-year revenue outlook while highlighting progress across its late-stage oncology pipeline, including lung cancer, breast cancer and mRNA cancer immunotherapy programs.

Diamondback Energy NASDAQ: FANG used its third-quarter 2026 earnings call to emphasize capital discipline, Permian Basin development and longer-term opportunities in natural gas, enhanced oil recovery and power infrastructure.

Fiserv NASDAQ: FISV reported third-quarter results that were in line with its expectations, with organic revenue flat year over year as the payments and financial-services company said it moved past its second-quarter revenue trough. Management reaffirmed its full-year outlook, projected a return to organic growth in both major segments during the fourth quarter, increased its Project Elevate savings target to $1 billion, and announced plans to repurchase $500 million of stock in the fourth quarter.

Capital Southwest NASDAQ: CSWC reported second-quarter fiscal 2027 pre-tax net investment income of $37.2 million, or $0.58 per share, supported by higher cash interest income and fee income as the business development company expanded its investment portfolio.

Hamilton Lane NASDAQ: HLNE reported fiscal second-quarter 2027 results marked by growth in fee-earning assets, management and advisory fees, and fee-related earnings, while outlining leadership changes, fundraising activity and new technology partnerships.

Henry Schein NASDAQ: HSIC reported third-quarter results marked by higher U.S. dental merchandise sales, margin expansion and improved underlying earnings, while raising its full-year non-GAAP earnings outlook.

AppLovin Corporation (NASDAQ:APP) will report third-quarter earnings after the close tomorrow, Nov. 4.